BeOne Medicines（百济神州）2026年中报：收入+32.3%至32.2亿美元，净利润4.64亿美元，BRUKINSA半年销售23.4亿美元

BeOne Medicines Ltd. (06160.HK) reported unaudited interim results for the six months ended June 30, 2026, highlighting strong revenue growth, higher net income, continued investment in research and development and progress across its global oncology business.
Total revenues increased 32.3% to approximately US$3.22 billion from US$2.43 billion in the prior-year period.
The company reported net income of approximately US$464.4 million, or US$0.31 per share, compared with net income of US$95.6 million, or US$0.07 per share, in the corresponding period of 2025.
The company said the strong financial performance reflected strong demand for its commercial portfolio, led by BRUKINSA, as well as disciplined operational execution and continued expansion across key global markets.
Financial Performance
Total revenues for the first half of 2026 reached approximately US$3.22 billion, compared with US$2.43 billion in the same period of 2025, driven by net product revenue of approximately US$3.17 billion, up 31.4% year over year.
Gross profit increased to approximately US$2.88 billion from US$2.10 billion, while income from operations rose to approximately US$574.9 million from US$99.0 million a year earlier.
Research and development expenses increased to approximately US$1.15 billion from US$1.01 billion, reflecting continued investment in the company's clinical pipeline and novel treatment modalities.
Selling, general and administrative expenses increased to approximately US$1.15 billion from US$997.2 million, primarily supporting the company's global commercialization activities.
The company reported basic and diluted earnings per share of US$0.32 and US$0.31, respectively, compared with US$0.07 for both basic and diluted EPS in the prior-year period.
The company reported net income of approximately US$464.4 million, compared with US$95.6 million a year earlier.
Pipeline And Commercial Progress
BRUKINSA generated net product sales of approximately US$2.34 billion during the first half of 2026, up from US$1.74 billion in the first half of 2025, supported by market share expansion across major indications globally.
TEVIMBRA delivered net sales of approximately US$434.8 million, compared with US$364.7 million in the prior-year period, as international commercialization continued to expand.
The company also maintained solid performance from in-licensed products in China, including XGEVA, which generated approximately US$194.4 million in sales, and BLINCYTO, which generated approximately US$70.6 million.
BeOne continued advancing its clinical pipeline across hematology and solid tumor programs while investing approximately US$1.15 billion in research and development during the period.
The company also advanced construction of its flagship manufacturing and clinical R&D facility in Hopewell, New Jersey, with construction in progress reaching approximately US$95.8 million.
Most of the facility is expected to be placed into service during 2026.
Cash Position And Outlook
BeOne maintained a strong financial position, generating positive operating cash flow of approximately US$664.2 million during the first half of 2026, compared with US$307.7 million in H1 2025.
Cash and cash equivalents totaled approximately US$5.10 billion as of June 30, 2026.
Total shareholders' equity increased to approximately US$5.17 billion.
Looking ahead, BeOne plans to leverage its financial position, operational infrastructure and global commercial network to advance its clinical-stage pipeline, strengthen its position in oncology and expand access to cancer therapies worldwide.
6160.HK has traded between $153.0 and $235.6 over the past year. The stock closed Wednesday's trading at $228.2, up 2.24%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.